Hemispherx BioPharma (HEB)

[STOCK_MOMO]

Hemispherx Announces Strategic Relationship With Squire Patton Boggs, Washington, DC as Governmental Counsel in Fight Against Ebola

PHILADELPHIA, Oct 20, 2014 (GLOBE NEWSWIRE via COMTEX) -- Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx"), has retained Squire Patton Boggs (SPB) to serve as its global government relations team in an effort to help find additional pathways for testing Hemispherx's flagship experimental anti-viral Ampligen(R) and approved anti-viral (HPV) Alferon(R) N against the devastating Ebola virus. Hemispherx currently is testing its experimental immunomodulator Ampligen(R) for potential efficacy as a prophylactic and therapeutic against the Ebola virus, (http://www.hemispherx.net/content/investor/default.asp?goto=796 and http://www.hemispherx.net/content/investor/default.asp?goto=797). Squire Patton Boggs will work with foreign officials in Africa, Europe and the United States, to pursue opportunities to provide Ampligen(R) and Alferon(R) to populations suffering from the Ebola crisis.
Mr. Thomas Equels, Executive Vice Chairman of Hemispherx, stated, "We are pleased to establish a strategic relationship with SPB, one of the world's finest governmental, international relations, biopharma licensing and corporate M&A law firms. We welcome SPB to the Hemispherx team effort to bring our experimental drug Ampligen(R) and FDA approved drug Alferon(R) N online as potential therapeutics for Ebola and other lethal viruses for which no effective therapy exists. This strategic alliance will dramatically enhance our future efforts to try to save lives and alleviate human suffering resulting from these lethal worldwide threats."